Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Published:2021-02 Issue:10273 Volume:397 Page:475-486
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Gordon Kenneth B,Foley Peter,Krueger James G,Pinter Andreas,Reich Kristian,Vender Ronald,Vanvoorden Veerle,Madden Cynthia,White Katy,Cioffi Christopher,Blauvelt Andrew

Funder

AbbVie

Bristol-Myers Squibb

UCB Pharma

Eli Lilly and Company

Roche Diagnostics

GlaxoSmithKline Australia

Amgen

Celgene

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Treatment approaches to moderate to severe psoriasis;Gisondi;Int J Mol Sci,2017

2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Sbidian;Cochrane Database Syst Rev,2020

3. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR);Warren;J Invest Dermatol,2015

4. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy;Brezinski;PLoS One,2012

5. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting;Bonafede;J Dermatol Treat,2013

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

3. Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis);Journal of Dermatological Treatment;2024-08-20

4. Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24‐week real‐world study;The Journal of Dermatology;2024-08-12

5. The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations;Expert Opinion on Biological Therapy;2024-08-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3